Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor β receptor fusion oncogene

1 Aug 2002

Abstract excerpt

Platelet-derived growth factor beta receptor (PDGFbetaR) fusion genes have been shown to be critical transforming oncogenes in a subset of patients with chronic myelomonocytic leukemia (CMML). The sensitivity of dysregulated tyrosine kinase oncogenes to the tyrosine kinase inhibitor STI571 (imatinib mesylate) makes it a potentially attractive treatment option in this subset of patients. We have recently cloned a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12130532
DOI: 10.1182/blood-2002-01-0165

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor β receptor fusion oncogenePMID 12130532Read ↗

Rabaptin-5 is a novel fusion partner to platelet-derived growth factor β receptor in chronic myelomonocytic leukemiaSemantic proximity Read ↗

Molecular targets in acute myelogenous leukemia.Semantic proximity Read ↗

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.Semantic proximity Read ↗

[STI571: a summary of targeted therapy].Semantic proximity Read ↗

The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways.Semantic proximity Read ↗

Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor geneSemantic proximity Read ↗

Molecular mechanisms of resistance to STI571 in chronic myeloid leukemiaSemantic proximity Read ↗

Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplificationSemantic proximity Read ↗

Durable responses to imatinib in patients with PDGFRB fusion gene–positive and BCR-ABL–negative chronic myeloproliferative disordersSemantic proximity Read ↗

[Novel inhibitors of Bcr-Abl].Semantic proximity Read ↗

Fusion of <i>PDGFRB</i> to two distinct loci at 3p21 and a third at 12q13 in imatinib‐responsive myeloproliferative neoplasmsSemantic proximity Read ↗

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.